Corcept Therapeutics (NASDAQ:CORT) Insider Sells $817,400.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total value of $817,400.00. Following the completion of the transaction, the insider directly owned 1,235 shares of the company’s stock, valued at approximately $50,474.45. This represents a 94.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

William Guyer also recently made the following trade(s):

• On Tuesday, January 6th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $35.18, for a total transaction of $703,600.00.
• On Tuesday, December 2nd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $80.08, for a total transaction of $1,601,600.00.
• On Tuesday, November 25th, William Guyer sold 4,500 shares of Corcept Therapeutics stock. The stock was sold at an average price of $80.90, for a total transaction of $364,050.00.

Corcept Therapeutics Trading Up 6.4%

NASDAQ:CORT opened at $40.83 on Friday. The stock has a market cap of $4.29 billion, a price-to-earnings ratio of 46.40 and a beta of 0.25. The company has a quick ratio of 3.07, a current ratio of 3.14 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average price is $58.17 and its 200-day moving average price is $69.08. Corcept Therapeutics Incorporated has a 52 week low of $32.99 and a 52 week high of $117.33.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors have recently bought and sold shares of CORT. Prescott Group Capital Management L.L.C. bought a new stake in Corcept Therapeutics during the fourth quarter valued at about $3,132,000. PNC Financial Services Group Inc. lifted its position in shares of Corcept Therapeutics by 18.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 17,575 shares of the biotechnology company’s stock valued at $612,000 after buying an additional 2,775 shares in the last quarter. Handelsbanken Fonder AB grew its stake in shares of Corcept Therapeutics by 13.8% during the 4th quarter. Handelsbanken Fonder AB now owns 28,781 shares of the biotechnology company’s stock valued at $1,002,000 after acquiring an additional 3,500 shares during the period. Allworth Financial LP increased its holdings in Corcept Therapeutics by 13.6% in the 4th quarter. Allworth Financial LP now owns 10,333 shares of the biotechnology company’s stock worth $360,000 after acquiring an additional 1,237 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its holdings in Corcept Therapeutics by 1.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 21,372 shares of the biotechnology company’s stock worth $744,000 after acquiring an additional 293 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CORT has been the topic of several research analyst reports. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a report on Friday, January 23rd. HC Wainwright increased their price objective on shares of Corcept Therapeutics from $90.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Wall Street Zen lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, October 18th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $83.50.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Analyst support — several firms have recently raised price targets and maintained buy views (HC Wainwright, Canaccord among others), which can lift sentiment and buying interest for CORT.
• Positive Sentiment: Longer‑term performance story — coverage highlighting that investors are up materially over a multi‑year period helps justify accumulation for some holders and frames today’s move as part of a broader recovery narrative. Despite lower earnings than three years ago, Corcept Therapeutics (NASDAQ:CORT) investors are up 71% since then
• Neutral Sentiment: Short‑interest data appears non‑informative — the reported short interest shows 0 shares (likely a data/reporting artifact), so short pressure is not a meaningful current driver.
• Neutral Sentiment: Recent fundamentals — the company’s last reported quarter missed EPS and revenue estimates (Nov 4 release), which remains in the background for investors weighing valuation vs. growth prospects.
• Negative Sentiment: Multiple securities‑law investigations — several plaintiff firms (Kaplan Fox & Kilsheimer, Bernstein Liebhard, Schall Law Firm, DJS Law Group) have announced probes into Corcept, alleging possible disclosure or misstatement issues; that increases litigation risk, news flow uncertainty, and potential future liabilities. CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Bernstein Liebhard investigation alert Schall Law Firm investigation DJS Law Group investigation
• Negative Sentiment: Insider selling — director William Guyer sold 20,000 shares at about $40.87 (filed with the SEC), substantially reducing his stake; large insider sales often spur caution among investors and can pressure the stock. SEC filing: insider sale

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.